NCT02741024View on ClinicalTrials.gov

Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo

PHASE4CompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Malaria
Interventions
DRUG

Amodiaquine-Artesunate (ASAQ)

Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home

DRUG

Artemether-Lumefantrine (AL)

Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.

All Listed Sponsors
lead

Medecins Sans Frontieres, Netherlands

OTHER

NCT02741024 - Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo | Biotech Hunter | Biotech Hunter